Prothena price target raised to $62 from $58 at Oppenheimer

Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a uniquely favorable risk/reward setup for investors ahead of the Phase 3 AFFIRMAL readout for birtamimab in AL amyloidosis expected in the first half of 2025.